Hactosec

Form: Syrup
Dosage: 150ml
Packaging: Suspension for oral use

Active substance : levodropropizine

Form : Syrup

Dosage : Each ml of syrup contains 6 mg of levodropropizine (30 mg/5ml)

Packaging :

Cardboard box including 150 ml of syrup in a  glass bottle closed and a plastic dosing device.

Target :

Children as from 2 years of age up to adults

Hactosec is indicated  for the Symptomatic treatment of dry cough (non-productive, disturbing cough).

Adults and children from 12 years and older

  • Maximum 60 mg levodroprozine (10 ml syrup), three times daily. The time between administrations should be at least 6 hours.

Pediatric population

Children 6 to 12 years

  • 12 mg to maximum 30 mg levodropropizine (2 ml to maximum 5 ml syrup) three times daily. The time between administrations should be at least 6 hours.

Children 2 to 6 years

  • 12 mg to 18 mg levodropropizine (2 ml to 3 ml syrup), maximum three times daily. The time between administrations should be at least 6 hours.

The usual dose is 1 mg to 2 mg per kg of bodyweight (eq. with 0.15 ml to 0.3 ml of syrup).

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma